Why Guardant Health’s (GH) 2026 Screening Story Reinforced Piper Sandler’s Bullish View

Guardant Health, Inc. (NASDAQ:GH) is 1 of the best maturation stocks to bargain according to billionaires.

As of March 13, 2026, Guardant Health carried a Moderate Buy statement from 23 analysts, based connected 21 Buy ratings, 1 Hold, and 1 Sell. The mean 12-month terms people stood astatine $122.57, implying astir 43% upside from the caller stock terms of $85.49, portion the published people scope ran from $55 to $180.

The bullish code came aft a agelong of institution updates that gave analysts much to enactment with than a azygous net print. On February 19, 2026, Guardant Health reported fourth-quarter 2025 gross of $281.3 million, up 39% twelvemonth implicit year, with oncology gross rising 30% to $189.9 cardinal and screening gross reaching $35.1 million. The institution said it expects full 2026 gross to turn 27% to 30%.

Tonhom1009/Shutterstock.com

Management past added much item astatine the Leerink Global Healthcare Conference connected March 10, 2026, and the Barclays 28th Annual Global Healthcare Conference connected March 11, 2026. At those events, Guardant highlighted its Quest Diagnostics concern arsenic a cardinal commercialized lever for Shield and said immoderate upside from Quest’s co-promotion was not included successful 2026 guidance. The institution besides said 90% of Shield users had not been screened successful the anterior 5 years, reinforcing its presumption that Shield tin grow the screening marketplace alternatively than conscionable vie wrong it. Management besides pointed to further portfolio catalysts, including imaginable FDA-related advancement tied to ESR1 monitoring successful Guardant360, portion noting that Reveal Ultra was excluded from 2026 guidance due to the fact that reimbursement remains uncertain.

Against that backdrop, Piper Sandler expert David Westenberg maintained a Buy standing and $130 terms people connected March 11, 2026, aft raising his people from $120 to $130 connected February 24, 2026, pursuing the company’s quarterly release.

Guardant Health, Inc. (NASDAQ:GH) is simply a precision oncology institution that develops blood-based tests for crab screening, attraction selection, and recurrence monitoring.

While we admit the imaginable of GH arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years

Disclosure: None. Follow Insider Monkey connected Google News.